Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT05305924
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
28
Enrollment
OTHER
Sponsor class
Conditions
ER-Positive Breast Cancer
HER2-negative Breast Cancer
Interventions
DRUG:
Fulvestrant Run-In
Sponsor
The Methodist Hospital Research Institute
Collaborators
[object Object]